Zymeworks Total Assets 2016-2021 | ZYME

Zymeworks total assets from 2016 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Zymeworks Annual Total Assets
(Millions of US $)
2020 $538
2019 $368
2018 $244
2017 $132
2016 $94
2015 $23
Zymeworks Quarterly Total Assets
(Millions of US $)
2021-09-30 $420
2021-06-30 $472
2021-03-31 $490
2020-12-31 $538
2020-09-30 $572
2020-06-30 $607
2020-03-31 $637
2019-12-31 $368
2019-09-30 $400
2019-06-30 $415
2019-03-31 $238
2018-12-31 $244
2018-09-30 $194
2018-06-30 $211
2018-03-31 $114
2017-12-31 $132
2017-09-30 $100
2017-06-30 $115
2017-03-31 $80
2016-12-31 $94
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $23
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.697B $0.039B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69